Financial Statements for the Financial Year 2014

  • Extensive write-downs have a negative effect on the annual result of the financial year 2014
  • Further need to write down and retirement from the stock exchange are being analysed.
 

Frankfurt / Main – June 26, 2015 – Nanostart AG is today publishing its annual financial statements for the financial year 2014. The financial year 2014 is concluded with a loss of EUR 8.88 million. Results were considerably impacted by value adjustments totalling EUR 8.40 million. The value adjustments refer to write-downs at ItN Nanovation AG, at Namos GmbH and in part to value adjustments at New Asia Investments Pte. Ltd., which was necessary due to the write-down of BioMers Pte. Ltd., as well as the loans to the subsidiary, VentureTech Equity-Partners GmbH.

Read more ...

Nanostart AG: Mr Neef's appointment as CEO extended

  • Neef's activity as CEO has been extended
 

Frankfurt am Main – 20 March 2015 – Nanostart AG announces that according to the Supervisory Board's resolution, dated 19 March 2015, Mr Neef's appointment as CEO was extended until 31 December 2015. Up to now, Mr Neef was appointed as interim CEO.

Read more ...

Nanostart AG: New Board of Directors appointed

  • Bernd Förtsch has become member of the Board of Directors
 

Frankfurt am Main – 10 February 2015 – The Nanostart AG announces that the District Court Frankfurt am Main has met the request of the Executive Board of the Nanostart AG by means of the decision in January 2015, appointing Mr Bernd Förtsch as member of the company’s Board of Directors.

 

Read more ...

Nanostart AG publishes annual accounts for the 2013 financial year

  • Nanostart AG achieved a net profit of EUR 0.34 million after tax
  • Company virtually free of liabilities (previous year EUR 3.81 million)
  • Operating expenses reduced by 54.8 percent
 

Frankfurt / Main – July 1, 2014 - The Frankfurt-based nanotechnology investment company Nanostart AG is today publishing its annual financial statements for the 2013 financial year. The company posted a net profit of EUR 0.34 million according to HGB (German Commercial Code).

Read more ...

Nanostart-holding MagForce AG: MagForce AG and MagForce USA, Inc. Announce FDA Pre-IDE Meeting

  

Frankfurt / Berlin, Germany and Nevada, USA - May 5, 2014 – Nanostart-holding MagForce, a leading medical device company in the field of nanomedicine focused on oncology, together with its subsidiary MagForce USA, Inc. are pleased to report that an in-person meeting was held with the U.S. Food and Drug Administration’s (FDA) Center for Devices and Radiological Health to discuss FDA’s response to MagForce’s NanoTherm® Therapy Pre-Submission of late December, 2013.

Read more ...

Press Contact

Tel.:  +49 (0)69-2193 96 00
Fax.:  +49 (0)69-2193 96 150
E-Mail: presse@nanostart.de

Subscribe